Notable Etf Inflow Detected – Xbi, Aria, Nbix, Geva

investors once converted back into their stronger U.S. dollar. Expectations of Mt. Gox’s failure have been building for weeks. Now that it is finally evident, perhaps the price of the crypto-currency can move higher.

Components of that ETF showing particular strength include shares of InterMune (ITMN), up about 166% and shares of Cepheid (CPHD), up about 2.3% on the day. And underperforming other ETFs today is the Junior Gold Miners ETF (GDXJ), down about 1.9% in Tuesday afternoon trading. Among components of that ETF with the weakest showing on Tuesday were shares of Allied Nevada Gold (ANV), lower by about 6%, and shares of Aurcana (AUN.CA), lower by about 5.5% on the day.

( ARIA ) is up about 1.9%, Neurocrine Biosciences, Inc. ( NBIX ) is up about 0.7%, and Synageva BioPharma Corp ( GEVA ) is up by about 2.3%. For a complete list of holdings, visit the XBI Holdings page Click here to find out which 9 other ETFs had notable inflows The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI’s low point in its 52 week range is $91.15 per share, with $171.09 as the 52 week high point that compares with a last trade of $169.20. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique — learn more about the 200 day moving average . Exchange traded funds (ETFs) trade just like stocks, but instead of ”shares” investors are actually buying and selling ”units”.
Source:–xbi-aria-nbix-geva.html The First Trust ETF is closely tied to the index in its name, the NYSE Arca Biotechnology Index /quotes/zigman/6017893/realtime BTK . That index made a corresponding gain of 5.75% to 2,946.43, thanks largely to InterMunes massive price increase. InterMune /quotes/zigman/85637/delayed /quotes/nls/itmn ITMN ended its phenomenal day with a whopping $23.84 per-share gain to $37.80. Food and Drug Administration, and it planned to refile an application with regulators in the third quarter.

If you wish to view more, click the button below. The Financial Times Ltd 2014 FT and ‘Financial Times’ are trademarks of The Financial Times Ltd. Printed from: Print a single copy of this article for personal use. Contact us if you wish to print more to distribute to others. The Financial Times Ltd 2014 FT and Financial Times are trademarks of The Financial Times Ltd. Privacy policy | Terms | Copyright

Another Reason to Study Your Biotech ETF’s Holdings

That being the SPDR S&P Biotech ETF ( XBI ) where Intercept is now the largest holding at almost 6.8% of the ETFs weight. [ Why This Biotech Leads the Pack ] A similar scenario is playing out again Tuesday with the First Trust NYSE Arca Biotechnology Index Fund ( FBT ) soaring over 5% on a day when etf investing strategy two of the other four biotech ETFs are lower and only one of the two, XBI, is higher by any noteworthy amount. FBT is the only biotech ETF with notable exposure to InterMune ( ITMN ), shares of which are up more than 150% after the company said its lung disease drug Esbriet met its goals in a late-stage clinical trial intended to help InterMune win marketing approval for the drug in the U.S., according to the Associated Press . As of Monday, FBT had a 3.6% weight to InterMune, making the stock the smallest of the ETFs 20 holdings. However, no other FBT holding has an allocation of more than 7.02% . Importantly, no other biotech ETF has a weight of more than 1.14% to InterMune. The ETF that has that weight is XBI, hence why it is the second-best biotech ETF behind FBT Tuesday.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s